o heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
VANDA PHARMACEUTICALS INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)Three Months EndedTwelve Months EndedDecember 31December 31December 31December 31(In thousands, except for per share amounts)
26,789Royalty revenue 1,6185114,4813,141Product sales---5,290Grant revenue-489-489Total revenues8,3707,75231,27035,709Operating expenses:Cost of sales - product ---2,891Research and development 10,5563,82228,99612,338General and administrative 3,3452,76211,48610,147Intangible asset amortization 3773771,4951,495Total operating expenses14,2786,96141,97726,871Income (loss) from operations (5,908)791(10,707)8,838Other income:Interest income99142461431Total other income99142461431Income (loss) before income tax(5,809)933(10,246)9,269Provision (benefit)Tax provision (benefit)(286)(1,266)(444)2,077Net income (loss)
7,192Net income (loss)per share:Basic
0.25Shares used in calculation of net income (loss) per share:Basic
28,106,83127,916,388Diluted28,115,17528,892,34728,106,83128,534,617VANDA PHARMACEUTICALS INC.CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)(In thousands)
December 31, 2011December 31, 2010ASSETSCurrent assets:Cash and cash equivalents
Page: 1 2 3 4 5 6 7 8 Related medicine technology :1
|SOURCE Vanda Pharmaceuticals Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Vanda Pharmaceuticals Submits Iloperidone New Drug Application2
. Vanda Pharmaceuticals Reports Third Quarter 2007 Results3
. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application4
. Vanda Presents Phase III Iloperidone Efficacy Data5
. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia6
. Vanda Pharmaceuticals Provides Update on Iloperidone7
. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet8
. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia9
. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia10
. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)11
. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.